
Precision Cancer Medicine Program
At UCSF, we believe cancer therapy works best when it's tailored to the patient. Our Pediatric Precision Cancer Medicine Program makes this personalized care possible for children, teens and young adults with any kind of cancer, including cancers that are rare, high-risk or resistant to standard therapies.
Our team uses leading-edge tools, such as the UCSF500 Cancer Gene Panel, to identify the genetic signatures of a patient's disease. These findings can help us diagnose cancers more precisely and allow us to design personalized treatment plans that maximize effectiveness while minimizing side effects. We also work alongside other UCSF specialists to make sure all our patients receive care that's comprehensive, top-notch and compassionate.
What's more, our doctors are leaders in national research groups dedicated to childhood cancers, including leukemia, neuroblastoma and pediatric brain tumors. This means our patients can access treatments that are still being tested in clinical trials. We're the only Northern California hospital that's part of the National Cancer Institute's Pediatric Early Phase Clinical Trials Network, a small group of top institutions tasked with developing new therapies for cancers affecting kids.
Many of the precision cancer services we provide are not readily available at other hospitals, and some are offered only at UCSF. Yet patients who don't live near the Bay Area can still benefit from our expertise: We work with oncologists throughout the country and world to analyze tumor samples and guide treatments that can be administered by the patient's local care team.
Request appointment
To schedule an appointment with the Pediatric Precision Cancer Medicine Program, please give us a call at (415) 476-3831.
Please note that many insurance plans require a referral from your child's primary care physician before you schedule a visit at UCSF. We ask that you contact your insurance carrier to check if you need an authorization before your appointment. If a referral is required, please ask your child's primary care physician to fax a referral form and any applicable medical records to the UCSF Pediatric Access Center at (415) 353-4485.
Our locations (1)
Highlights of our cancer care

Leading-edge treatments
We're among the first to offer new treatment options, as soon as they're proven safe and effective. In addition, patients can access promising experimental therapies by participating in one of our many clinical trials.
Precision medicine
High-risk tumors are analyzed with the UCSF500 Cancer Gene Panel, a state-of-the-art test that identifies mutations in the tumor's DNA. The results can indicate the best treatment course and, in some cases, clarify the exact type of cancer.
Seamless care, near and far
Dedicated patient navigators help families with managing referrals, insurance concerns and appointment planning. We work with patients and referring doctors well beyond the San Francisco Bay Area, thanks to our comprehensive telehealth system.
Thorough follow-up
Our Pediatric Survivorship Program provides expert care to address any medical, psychological or social issues that arise after treatment is complete. The team also ensures smooth transitions to adult care providers as our patients leave childhood behind.

Our team
-
Anuradha Banerjee
MD
Pediatric neuro-oncologist -
Robert E. Goldsby
MD
Pediatric hematologist-oncologist -
Arun Rangaswami
MD
Pediatric hematologist-oncologist -
Alyssa Reddy
MD
Pediatric neurologist and neuro-oncologist -
Amit J. Sabnis
MD, MS
Pediatric hematologist-oncologist -
Elliot Stieglitz
MD
Pediatric hematologist-oncologist -
Alejandro Sweet-Cordero
MD
Pediatric hematologist-oncologist -
Kieuhoa T. Vo
MD
Pediatric hematologist-oncologist
Awards & recognition
-
Best in Northern California for cancer care
-
Ranked among the nation's best in 11 specialties
-
Designated an early phase clinical trials core site by the Children's Oncology Group
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your child's condition
- List of medications, including dosages, plus any your child is allergic to
- List of questions you may have
- Device or paper for taking notes
Related clinics (5)

Blood & Marrow Transplant (BMT) Clinic

Orthopedic Surgical Oncology Clinic
Support services
Clinical trials
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Will be estimated for eligible and evaluable patients assigned to Stratum 1 using Kaplan-Meier (KM) EFS estimates at 2 and 3 years with respective 80% two-sided confidence intervals. Time from initiation of radiation to the first ...
Recruiting
More about this studyA Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Gli...
The Kaplan-Meier method will be used to estimate EFS which is defined as the interval from randomization to first occurrence of clinical or radiographic disease progression, disease recurrence, second malignant neoplasm, or death ...
Recruiting
More about this studyInotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL...
Improvement in 5-year disease-free survival (DFS) with modified Berlin-Frankfurt-Münster (mBFM) chemotherapy without delayed intensification (DI) part 2 but with inotuzumab ozogamicin, versus full mBFM chemotherapy backbone includ...
Recruiting
More about this studyA Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Will be measured by the number of progressions or deaths within 2 years of enrollment for the cohort treated with whole ventricular + spinal canal irradiation (WVSCI). The final analysis will include an exact binomial confidence i...
Recruiting
More about this studyThe Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in...
The proportion will be calculated as the percent of eligible patients who are identified to have an a priori specified genomic or immunophenotypic target and who enroll on at least one of the sub-trials. The corresponding confiden...
Recruiting
More about this studyVenetoclax Basket Trial for High Risk Hematologic Malignancies
To determine the maximum tolerated dose (MTD of venetoclax given in combination with regimen-prescribed chemotherapy. The MTD is defined as the dose level associated with observed DLTs in <33% of enrolled subjects
Recruiting
More about this studyTegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and D...
The number of patients experiencing a cycle 1 dose limiting toxicity at least possibly attributable to tegavivint by study part and dose level.
Recruiting
More about this studyA Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or R...
Regimen A Cycle 1 will be used for determination of recommended phase 2 dose (RP2D)-lymphoid (L) directed chemotherapy block. A patient will be considered as being evaluable for DLT if: (1) the patient receives at least 66 doses o...
Recruiting
More about this studyA Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Will estimate the number and percentage of patients with >= grade 2 hearing loss using the society of pediatric oncology (SIOP) scale (defined as hearing threshold >20 dB at >= 4kHz) 4 weeks after the last dose of cisplatin. If he...
Recruiting
More about this studyCBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymp...
Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of CBL0137 in children with relapsed or refractory solid tumors including CNS tumors and lymphoma.
Recruiting
More about this studyOur research initiatives
Fetal surgery firsts
The first open fetal surgery in the world was performed at UCSF in the early 1980s.
